Epidemiological delays are key quantities that inform public health policy and clinical practice. They are used as inputs for mathematical and statistical models, which in turn can guide control strat...

Importance  Dengue outbreaks are increasing in frequency and intensity. In the absence of any specific treatment, a pan-serotype recombinant monoclonal antibody (Dengue-mAb) was tested in adult patients with dengue as a therapeutic option.Objective  To assess the safety and effect of a single dose of Dengue-mAb on dengue viremia at different dose levels among patients with dengue.Design, Setting, and Participants  A phase 2, single-blind, randomized, placebo-controlled clinical trial was conducted from September 19, 2021, to May 13, 2023, at 12 hospitals in India. Study participants were aged 18 to 60 years with dengue and a history of fever onset within 48 hours. Key exclusion criteria were severe dengue, hemoglobin less than 10 g/dL, absolute neutrophil count less than 500/mm3, total leukocyte count less than 1500/mm3, platelet count less than 50 000/mm3, and any other clinically significant disorders. Data were analyzed from January 11, 2024, to March 26, 2024.Interventions  Participants were randomly allocated 1:1:1:1:1 using an interactive web response system to receive 1 of 4 dose levels of Dengue-mAb (3, 5, 7, or 9 mg/kg) or placebo by slow intravenous infusion.Main Outcomes and Measures  Primary outcomes were reduction in viremia at 24 hours and causally related serious adverse events (SAEs). Secondary outcomes were RNAemia, fever, and hematologic and pharmacokinetic parameters.Findings  A total of 250 participants were randomized, with 50 participants in each group. The overall median age was 30 years (IQR, 24-37 years), and 180 participants (72.3%) were male. There were no causally related SAEs. The adjusted mean (SE) viral log reduction at 24 hours was significantly higher with Dengue-mAb—from 1.93 (0.23) with 3 mg/kg (P = .04) to 2.35 (0.27) with 9 mg/kg (P = .003)—compared with placebo (1.29 [0.22]), using a mixed model for repeated measures. Participants with detectable viremia (n = 32) at baseline were negative for dengue virus by 8 hours when treated with a 5- to 9-mg/kg dose of Dengue-mAb compared with 72 hours with placebo. Median time to fever clearance was 3.5 (95% CI, 1.0-24.0) hours (hazard ratio [HR], 2.6 [95% CI, 1.0-6.4]) with Dengue-mAb 5 mg/kg (n = 14) and 2.0 (95% CI, 0.5-6.0) hours (HR, 2.8 [95% CI, 1.2-6.8]) with Dengue-mAb 7 mg/kg (n = 14), compared with 26.8 (95% CI, 1.0-50.5) hours with placebo (n = 12). At 24 hours, between 13 of 14 participants (92.9%; 95% CI, 66.1%-99.8%) with Dengue-mAb (3 mg/kg), 14 of 14 participants (100.0%; 95% CI, 76.8%-100.0%) with Dengue-mAb (5 mg/kg and 7 mg/kg), and 16 of 17 participants (94.1%; 95% CI 71.3%-99.9%) with Dengue-mAb (9 mg/kg); and 7 of 12 participants (58.3%; 95% CI, 27.7%-84.8%) with placebo had fever clearance.Conclusions and Relevance  In this randomized clinical trial, Dengue-mAb was safe and well tolerated. Dengue-mAb rapidly reduced dengue viremia and fever at doses of 5 mg/kg and 7 mg/kg, making this the first therapeutic against wild-type dengue virus to show preliminary efficacy in humans.Trial Registration  Clinical Trial Registry-India Identifier: CTRI/2021/07/035290

County vaccination figures looked reassuring right up until the largest US measles outbreak in 30 years began. This is the story of building a 50,000-school dataset to find out why the averages were lying, and what surveillance looks like once you finally zoom in.

Even in large systems, the effect of noise arising from when populations are initially small can persist to be measurable on the macroscale. A deterministic approximation to a stochastic model will fa...

This study compiles and standardizes reported infectious disease transmission trees to analyze trends in superspreader frequency and generation; these data support theories that intermediate dispersio...

From Typhoid Mary to SARS, it has long been known that some people spread disease more than others. But for diseases transmitted via casual contact, contagiousness arises from a plethora of social and...

A mathematical model was used to establish a simple conceptual basis for why super-spreader events fundamentally drive the spread of SARS-CoV-2 but not influenza.

An epidemic’s expected course is determined by the magnitude and timing of a typical person’s infectiousness — captured, in turn, by the basic reproduction number and the generation-time distribution....

The Urgepi project is a measles emergency initiative implemented by Medecins Sans Frontieres Operational Centre Paris (MSF-OCP) in the Katanga region of the Democratic Republic of Congo, a setting cha...

Background & aims of study Current measles outbreaks around the world have highlighted the evolving immunity landscape of some vaccine-preventable diseases (VPDs). In Canada, there have been approxima...

Michael Kratsios, President Trump’s science adviser, proposed overhauling how the government funds research. Democrats said Mr. Trump’s actions had weakened science.

Communications Health - How understanding the diversity of perspectives and systems in governments can increase the impact of scientific research

An analysis of public comments on a White House proposal to change the way federal contracts and grants are doled out shows widespread opposition

Mandatory reviews by top health officials and checks for 235 disfavoured terms have left hundreds of vetted grant applications in administrative limbo.

While SARS-CoV-2 and influenza continue to place a significant burden on population health, within-household differences in decisions towards vaccination and seeking care across these two pathogens, a...

Published during this pandemic, Paul Farmer’s new book, “Fevers, Feuds, And Diamonds,” is important, as it presents a critical dissection of the Ebola outbreak in West Africa, and the lessons we can l...

Incorporating vaccination into mathematical models appears deceptively simple: models integrate vaccine-derived protections, such as reduced susceptibility to infection, using parameters informed by e...

Report - Estimation of the size of the outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo

Pursuant to paragraph 2 of Article 12 - Determination of a public health emergency of international concern, including a pandemic emergency of the International Health Regulations (2005) (IHR), the Di...